Type B patent ductus arteriosus.

Pediatr Cardiol

Department of Pediatrics, School of Medical Sciences, University Sains Malaysia, 16150 Kelantan, Kubang Kerian, Malaysia.

Published: May 2007

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00246-006-1398-9DOI Listing

Publication Analysis

Top Keywords

type patent
4
patent ductus
4
ductus arteriosus
4
type
1
ductus
1
arteriosus
1

Similar Publications

Background: The American College of Cardiology has published clinical practice algorithms for common congenital heart lesions, including atrial septal defect, patent ductus arteriosus, valvar pulmonary stenosis, aortic coarctation, and ventricular septal defect. The purpose of this study was to define the current practice patterns in the management of these lesions and describe the impact of departure from these recommendations.

Methods: This was a retrospective analysis of the most recent 100 outpatient appointments for each lesion at our centre.

View Article and Find Full Text PDF

Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors.

J Immunother Cancer

March 2025

St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK

Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes.

View Article and Find Full Text PDF

Visit-to-visit lipid variability and adverse kidney events in real-world type 2 diabetes patients.

Diabetes Res Clin Pract

March 2025

Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:

Aim: To examine the association between long-term variability in low-density lipoprotein cholesterol (LDL-C) and the development of adverse kidney events among type 2 diabetes patients.

Methods: Kidney events of interest included sustained estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m, 30 % eGFR decline, and composite kidney events.

View Article and Find Full Text PDF

PTPσ-mediated PI3P regulation modulates neurodegeneration in C9ORF72-ALS/FTD.

Neuron

March 2025

Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; The Solomon H. Snyder Department of Neuroscience and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address:

The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is the repeat expansion in C9ORF72. Dipeptide repeat (DPR) proteins translated from both sense and antisense repeats, especially arginine-rich DPRs (R-DPRs), contribute to neurodegeneration. Through CRISPR interference (CRISPRi) screening in human-derived neurons, we identified receptor-type tyrosine-protein phosphatase S (PTPσ) as a strong modifier of poly-GR-mediated toxicity.

View Article and Find Full Text PDF

Characterization of diverse Cas9 orthologs for genome and epigenome editing.

Proc Natl Acad Sci U S A

March 2025

Department of Biomedical Engineering, and Center for Advanced Genomic Technologies, Duke University, Durham, NC 27708.

CRISPR-Cas9 systems have revolutionized biotechnology, creating diverse new opportunities for biomedical research and therapeutic genome and epigenome editing. Despite the abundance of bacterial CRISPR-Cas9 systems, relatively few are effective in human cells, limiting the overall potential of CRISPR technology. To expand the CRISPR-Cas toolbox, we characterized a set of type II CRISPR-Cas9 systems from select bacterial genera and species encoding diverse Cas9s.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!